Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.

European journal of internal medicine - 1 Apr 2012

Javorsky Martin, Klimcakova Lucia, Schroner Zbynek, Zidzik Jozef, Babjakova Eva, Fabianova Maria, Kozarova Miriam, Tkacova Ruzena, Salagovic Jan, Tkac Ivan

Abstract excerpt

AIMS: Potassium inwardly rectifier 6.2 subunit (Kir6.2) of the ATP-sensitive potassium (K(ATP)) channel encoded by KCNJ11 gene is a therapeutical target for sulfonylureas. KCNJ11 E23K polymorphism was associated with type 2 diabetes in genetic association studies. The aim of the present pharmacogenetic study was to examine the effect of sulfonylurea treatment on glycemic control in relationship to KCNJ11 E23K...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Sulfonylurea Compounds
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Drug Therapy, Combination

Share to Hypoglycemic Agents

Share to Metformin

Share to Pharmacogenetics

Share to Potassium Channels, Inwardly Rectifying

Source

Identifiers

PMID: 22385882
DOI: 10.1016/j.ejim.2011.10.018

Genes

KCNJ11

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.PMID 22385882Read ↗

KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients.Semantic proximity Read ↗

The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.Semantic proximity Read ↗

KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.Semantic proximity Read ↗

The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.Semantic proximity Read ↗

Genetic Variants Identified from GWAS for Predisposition to Type 2 Diabetes Predict Sulfonylurea Drug Response.Semantic proximity Read ↗

Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms.Semantic proximity Read ↗

Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.Semantic proximity Read ↗

Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.Semantic proximity Read ↗

Neonatal diabetes due to potassium channel mutation: Response to sulfonylurea according to the genotype.Semantic proximity Read ↗

KCNJ11: Genetic Polymorphisms and Risk of Diabetes Mellitus.Semantic proximity Read ↗

KCNJ11: Genetic Polymorphisms and Risk of Diabetes MellitusSemantic proximity Read ↗

Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.